Posters & Publications :: Cellectar Biosciences, Inc. (CLRB)

CLR 131 in Patients with Relapsed or Refractory Pediatric Malignancies

Jan 6, 2021

Puccetti D, Otto M, Morgenstern D,DeSantes K,Cho SY, Hall L, Oliver K, Longcor J

Iopofosine I 131

ACR Annual Meeting Presentation<br><br>CLR 131 Demonstrates 100% Overall Response Rate in Relapsed or Refractory Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom’s Macroglobulinemia (WM): Initial Results from Ongoing Phase 2 trial, CLOVER-1 Study

Aug 17, 2020

S. Ailawadhi1, J. Longcor2, K. Oliver2, I. Grachev2

Iopofosine I 131

Interim Evaluation of a Targeted Radiotherapeutic, CLR 131, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients (R/R DLBCL)

Feb 10, 2020

J. Longcor1, K. Oliver1, J. Friend1, N. Callander2

Iopofosine I 131

CLR 2000045, a lipid raft targeted phospholipid-drug conjugate, shows potent activity against multiple breast cancer models including triple negative breast cancer

Dec 16, 2019

Longcor J, Hoover R, Pinchuk A

Targeted Delivery Platform, PDCs

Fractionated Dosing of CLR 131 in Patients With Relapsed or Refractory Multiple Myeloma (Rrmm)

Dec 9, 2019

Iopofosine I 131

CLR 180099, a lipid raft targeted phospholipid-drug conjugate, shows potent improved safety and efficacy against colorectal tumors

Oct 30, 2019

Longcor J, Hoover R, Pinchuk A

Targeted Delivery Platform, PDCs, PLEs